Post-COVID-19 pulmonary fibrosis: An ongoing concern
Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae includi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Annals of Thoracic Medicine |
| Subjects: | |
| Online Access: | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=4;spage=173;epage=181;aulast=Alrajhi |
| _version_ | 1797352285051813888 |
|---|---|
| author | Nuha Nasser Alrajhi |
| author_facet | Nuha Nasser Alrajhi |
| author_sort | Nuha Nasser Alrajhi |
| collection | DOAJ |
| description | Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both. |
| first_indexed | 2024-03-08T13:13:11Z |
| format | Article |
| id | doaj.art-53cb3973ff1744f4b0cfa059a752949a |
| institution | Directory Open Access Journal |
| issn | 1817-1737 1998-3557 |
| language | English |
| last_indexed | 2024-03-08T13:13:11Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Thoracic Medicine |
| spelling | doaj.art-53cb3973ff1744f4b0cfa059a752949a2024-01-18T10:33:53ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572023-01-0118417318110.4103/atm.atm_7_23Post-COVID-19 pulmonary fibrosis: An ongoing concernNuha Nasser AlrajhiCoronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 rapidly spread across the globe causing over 6 million deaths and major compromization of health facilities. The vast majority of survivors post-COVID-19 are left with variable degrees of health sequelae including pulmonary, neurological, psychological, and cardiovascular complications. Post-COVID-19 pulmonary fibrosis is one of the major concerns arising after the recovery from this pandemic. Risk factors for post-COVID-19 pulmonary fibrosis include age, male sex, and the severity of COVID-19 disease. High-resolution computed tomography provides diagnostic utility to diagnose pulmonary fibrosis as it provides more details regarding the pattern and the extent of pulmonary fibrosis. Emerging data showing similarities between post-COVID-19 pulmonary fibrosis and idiopathic pulmonary fibrosis, finding that needs further exploration. The management of post-COVID-19 pulmonary fibrosis depends on many factors but largely relies on excluding other causes of pulmonary fibrosis, the extent of fibrosis, and physiological impairment. Treatment includes immunosuppressants versus antifibrotics or both.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=4;spage=173;epage=181;aulast=Alrajhicovid-19pulmonary fibrosissevere acute respiratory syndrome coronavirus 2 |
| spellingShingle | Nuha Nasser Alrajhi Post-COVID-19 pulmonary fibrosis: An ongoing concern Annals of Thoracic Medicine covid-19 pulmonary fibrosis severe acute respiratory syndrome coronavirus 2 |
| title | Post-COVID-19 pulmonary fibrosis: An ongoing concern |
| title_full | Post-COVID-19 pulmonary fibrosis: An ongoing concern |
| title_fullStr | Post-COVID-19 pulmonary fibrosis: An ongoing concern |
| title_full_unstemmed | Post-COVID-19 pulmonary fibrosis: An ongoing concern |
| title_short | Post-COVID-19 pulmonary fibrosis: An ongoing concern |
| title_sort | post covid 19 pulmonary fibrosis an ongoing concern |
| topic | covid-19 pulmonary fibrosis severe acute respiratory syndrome coronavirus 2 |
| url | http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2023;volume=18;issue=4;spage=173;epage=181;aulast=Alrajhi |
| work_keys_str_mv | AT nuhanasseralrajhi postcovid19pulmonaryfibrosisanongoingconcern |